CTLA4 and melanoma: In melanoma patients, the toxicity of ipilimumab was shown to be dose-dependent (30, 31), while the high-grade toxicity observed with anti-PD-1/PD-L1 therapy did not seem to be dose-dependent and occurred at lower percentages than in the anti-CTLA-4 treatment (33–35).